Barinthus Biotherapeutics (BRNS) Total Non-Current Liabilities (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has 6 years of Total Non-Current Liabilities data on file, last reported at $24.2 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 3.22% year-over-year to $24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (down 3.22% YoY) and the FY2025 annual result came in at $22.4 million, down 22.31% from the prior year.
• Total Non-Current Liabilities grew to $24.2 million in Q1 2026, from $22.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $32.6 million in Q3 2023 to a low of $22.1 million in Q3 2025.
• A 5-year average of $27.1 million and a median of $26.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities advanced 12.24% — and 2025, when it fell 22.31%.
• Tracing BRNS's Total Non-Current Liabilities over 5 years: stood at $26.0 million in 2022, then declined by 1.35% to $25.7 million in 2023, then increased by 12.24% to $28.8 million in 2024, then dropped by 22.31% to $22.4 million in 2025, then grew by 8.02% to $24.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $24.2 million (Q1 2026), $22.4 million (Q4 2025), and $22.1 million (Q3 2025), per Business Quant data.